Business
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
Partnership will expand Firefly’s FDA Cleared BNA™ technology to more hospitals and physician offices TORONTO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Firefly
About this update from Firefly Neuroscience, Inc.
[{"type":"text","content":"Partnership will expand Firefly’s FDA Cleared BNA™ technology to more hospitals and physician offices\nTORONTO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced a strategic partnership with Zeto, Inc. (“Zeto”), a leading innovator in EEG brain monitoring technology. Under the agreement, Firefly will act as a non-exclusive distributor of Zeto’s FDA-cleared EEG headset devices, cloud platform and services, expanding Firefly’s accessibility to healthcare providers and institutions. This collaboration will also integrate Firefly’s proprietary Brain Network Analytics (BNA™) technology with Zeto’s advanced EEG platform, which is currently being used in more than 200 hospitals and neurology offices across the country. \"This collaboration of two progressive technology companies represents a major step forward in addressing an unmet medical need in brain health,\" said Jon Olsen, CEO of Firefly. \"By combining Zeto’s innovative hardware with our proprietary BNA™ technology, this partnership will offer healthcare providers deeper insights into neurological conditions that will ultimately improve patient outcomes.” Zeto’s EEG headsets - WR19 and Zeto ONE - are FDA-cleared, full-montage, and easy to use, making brain monitoring accessible across various clinical settings, including the ICU, ED, hospital, office, and home. Supported by a robust cloud-based platform, Zeto offers nationwide monitoring and interpretation services by neurologists, along with AI-powered seizure detection and video capabilities. As part of the distribution agreement, Firefly will offer Zeto’s devices and cloud services to its customers, allowing healthcare professionals to access, analyze, and store EEG data in real-time. The integration with Firefly’s BNA™ platform enables more precise analysis and expanded use of EEG technology, optimizing diagnostics for a wide range of neurological disorders. Zeto’s Founder and CEO, Aswin Gunasekar, stated, “We are excited to partner with Firefly to offer customers more valuable tools, helping expand our user base and improving the value of EEG. By integrating Firefly’s BNA™ offering wit...